Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Phathom Pharmaceuticals (PHAT) stock

Learn how to easily invest in Phathom Pharmaceuticals stock.

Phathom Pharmaceuticals, Inc

Phathom Pharmaceuticals, Inc is a biotechnology business based in the US. Phathom Pharmaceuticals shares (PHAT) are listed on the NASDAQ and all prices are listed in US Dollars. Phathom Pharmaceuticals employs 55 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Phathom Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PHAT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Phathom Pharmaceuticals stock price (NASDAQ: PHAT)

Use our graph to track the performance of PHAT stocks over time.

Phathom Pharmaceuticals shares at a glance

Information last updated 2021-07-23.
Latest market close$35.35
52-week range$30.74 - $50.78
50-day moving average $34.41
200-day moving average $38.33
Wall St. target price$58.17
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-10.08

Buy Phathom Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Phathom Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Phathom Pharmaceuticals price performance over time

Historical closes compared with the close of $35.35 from 2021-05-28

1 week (2021-07-15) N/A
1 month (2021-06-25) 1.00%
3 months (2021-04-26) -9.61%
6 months (2021-01-22) N/A
1 year (2020-07-22) N/A
2 years (2019-07-22) N/A
3 years (2018-07-22) N/A
5 years (2016-07-22) N/A

Phathom Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -34.02%
Return on equity TTM -77.08%
Profit margin 0%
Book value $5.69
Market capitalisation $1 billion

TTM: trailing 12 months

Shorting Phathom Pharmaceuticals shares

There are currently 1.2 million Phathom Pharmaceuticals shares held short by investors – that's known as Phathom Pharmaceuticals's "short interest". This figure is 19.3% up from 1.0 million last month.

There are a few different ways that this level of interest in shorting Phathom Pharmaceuticals shares can be evaluated.

Phathom Pharmaceuticals's "short interest ratio" (SIR)

Phathom Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Phathom Pharmaceuticals shares currently shorted divided by the average quantity of Phathom Pharmaceuticals shares traded daily (recently around 128431.73777315). Phathom Pharmaceuticals's SIR currently stands at 9.61. In other words for every 100,000 Phathom Pharmaceuticals shares traded daily on the market, roughly 9610 shares are currently held short.

However Phathom Pharmaceuticals's short interest can also be evaluated against the total number of Phathom Pharmaceuticals shares, or, against the total number of tradable Phathom Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Phathom Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Phathom Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0994% of the tradable shares (for every 100,000 tradable Phathom Pharmaceuticals shares, roughly 99 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Phathom Pharmaceuticals.

Find out more about how you can short Phathom Pharmaceuticals stock.

Phathom Pharmaceuticals share dividends

We're not expecting Phathom Pharmaceuticals to pay a dividend over the next 12 months.

Phathom Pharmaceuticals overview

Phathom Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. .

Frequently asked questions

What percentage of Phathom Pharmaceuticals is owned by insiders or institutions?
Currently 15.221% of Phathom Pharmaceuticals shares are held by insiders and 79.242% by institutions.
How many people work for Phathom Pharmaceuticals?
Latest data suggests 55 work at Phathom Pharmaceuticals.
When does the fiscal year end for Phathom Pharmaceuticals?
Phathom Pharmaceuticals's fiscal year ends in December.
Where is Phathom Pharmaceuticals based?
Phathom Pharmaceuticals's address is: 100 Campus Drive, Florham Park, NJ, United States, 07932
What is Phathom Pharmaceuticals's ISIN number?
Phathom Pharmaceuticals's international securities identification number is: US71722W1071
What is Phathom Pharmaceuticals's CUSIP number?
Phathom Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 71722W107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site